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Abstract
Research is uncovering the genetic and biochemical effects of consuming large
quantities of alcohol. One prime example is the J- or U-shaped relationship
between the levels of alcohol consumption and the risk of atherosclerotic
cardiovascular disease. Moderate alcohol consumption in humans (about 30 g
ethanol/d) is associated with reduced risk of coronary heart disease, while
abstinence and heavier alcohol intake is linked to increased risk. However, the
hepatic consequences of moderate alcohol drinking are largely unknown. Previous
data from alcohol-preferring (P) rats showed that chronic consumption does not
produce significant hepatic steatosis in this well-established model. Therefore, free-
choice alcohol drinking in P rats may mimic low risk or nonhazardous drinking in
humans, and chronic exposure in P animals can illuminate the molecular
underpinnings of free-choice drinking in the liver. To address this gap, we captured
the global, steady-state liver transcriptome following a 23 week free-choice,
moderate alcohol consumption regimen (,7.43 g ethanol/kg/day) in inbred alcohol-
preferring (iP10a) rats. Chronic consumption led to down-regulation of nine genes
in the cholesterol biosynthesis pathway, including HMG-CoA reductase, the rate-
limiting step for cholesterol synthesis. These findings corroborate our phenotypic
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analyses, which indicate that this paradigm produced animals whose hepatic
triglyceride levels, cholesterol levels and liver histology were indistinguishable from
controls. These findings explain, at least in part, the J- or U-shaped relationship
between cardiovascular risk and alcohol intake, and provide outstanding
candidates for future studies aimed at understanding the mechanisms that underlie
the salutary cardiovascular benefits of chronic low risk and nonhazardous alcohol
intake.
Introduction
The liver, the primary site of alcohol metabolism, is susceptible to many of the
pharmacological ramifications of drinking, and rodent models of human
consumption have been critical for elucidating these consequences. The ethanol-
containing Lieber-DeCarli [1] and the Tsukamoto-French intragastric liquid diets
[2] are widely accepted methods that produce maximal liver injury by force-
feeding rodents with ethanol. The Lieber-DeCarli approach delivers 12–18 g
ethanol/kg/day (d), with mean blood alcohol concentrations (BACs) reaching
290–380 mg/dL [3], while the Tsukamoto-French method achieves BACs as high
as 500 mg/dL. The liver develops many injuries in these forced ethanol
administrations, including: severe accumulation of macro- and microvesicular fat,
major structural and biochemical changes in organelles, activation of stellate cells,
evidence of early fibrosis and apoptosis.
However, it is becoming increasingly clear that not all pharmacological effects
of ethanol on liver processes are linearly related to ethanol dose and BAC levels.
One prime example is the J- or U-shaped relationship between increasing alcohol
consumption and the risk of atherosclerotic cardiovascular disease (not
cardiomyopathy). Several studies [4–6] and a large meta-analysis report [7]
concluded that light to moderate alcohol consumption in humans (i.e. 30 g
ethanol/d) is associated with a reduced risk of coronary heart disease and ischemic
stroke, while heavier alcohol intake is linked to increased risk. The underlying
mechanisms responsible for this well-documented J- or U-shaped relationship
remain unsolved. Suggested mechanisms include a complex interaction between
HDL and LDL cholesterol transfer dynamics in producing atherosclerosis, the
potential deleterious effects of ethanol on the biology of atherosclerotic plaques, as
well as oxidative stress, [8, 9]. Moderate alcohol consumption is inversely
correlated with metabolic syndrome and diabetes mellitus in obese individuals,
diabetes mellitus [10], as well as vascular dementia in the aging population [11].
To better model moderate levels of consumption, it is necessary to develop a
different paradigm. Most outbred rodents exhibit an innate aversion to voluntary
ethanol drinking and do not ingest enough ethanol to raise BACs to
pharmacological levels. One solution is to use the selectively bred alcohol-
preferring (P) rat. The P/NP (preferring/non-preferring) rat lines were raised by
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bidirectional selective breeding for divergent alcohol drinking preferences when
fed an ad libitum diet and given a free choice of drinking 10% (v/v) ethanol or
water [12, 13]. P rats must drink.5 g ethanol/kg/d whereas NP rats must drink
,1 g ethanol/kg/d. P rats typically drink 6.9¡0.2 g of ethanol/kg/d during the
dark cycle and attain BACs of 50–90 mg/dL within three hours. Behavioral studies
indicate that they accomplish this by drinking in several short spurts (1–4 bouts;
,6 minutes/bout) of.1 g of ethanol/kg/bout throughout the dark cycle.
Accordingly, P rats satisfy all the criteria proposed for an animal model of
alcoholism and meet many of the DSM-IV behavioral criteria for diagnosing
alcohol abuse and alcoholism [13–15]. With the foreknowledge that between-
species comparisons can be controversial, we suggest herein that the extent of free-
choice alcohol drinking in P rats, with respect to the liver, ostensibly models low
risk or nonhazardous alcohol drinking in humans.
Most hepatic transcriptome studies focus on high levels of forced ethanol
consumption that produced maximum liver steatosis and injury [16–18].
Although epidemiological evidence links light drinking with a protective effect,
there is a dearth of knowledge about the effects of free-choice drinking on the liver
in P animals. Therefore, the goals of this study were to: 1. Determine the effect of
nonhazardous alcohol quantities produced by chronic, free-choice drinking on
intrahepatic lipid accumulation and 2. Identify the hepatic gene networks that are
altered during long-term, nonhazardous, moderate alcohol usage. To address
these goals, we documented hepatic cholesterol and lipid levels and profiled the
hepatic transcriptome using RNA-Sequencing (RNA-Seq) following long-term
free-choice alcohol drinking. We report here that daily, voluntary consumption of
pharmacologically relevant levels of alcohol for 23 weeks alters expression of many
genes in the liver without causing hepatic steatosis. In congruence with the
phenotypic data, gene ontology analysis indicates that genes involved in
cholesterol synthesis are down-regulated in alcohol consuming animals. This
study, with a primary focus on the liver transcriptome, is consistent with the
involvement of the cholesterol pathway in the association between moderate
alcohol intake and reduced risk for heart disease and stroke.
Results
Several epidemiological studies link moderate alcohol intake with reduced risk for
coronary heart disease and ischemic stroke. Although, the molecular mechanisms
remain largely unsolved, top candidates are cholesterol dynamics, oxidative stress
and other unidentified biological effects of ethanol on atherosclerotic lesions. To
better understand the impact of moderate alcohol consumption on the liver, we
examined the effects of moderate, free-choice alcohol consumption on hepatic
triglyceride and cholesterol levels, as well as the hepatic transcriptome in animals
consuming ad libitum levels of alcohol for 23 weeks. To dampen the between-
animal variance, we used the inbred alcohol-preferring P rat strain, iP10a.
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Lack of steatosis and normal lipid profiles in both groups
Chronic, high dose ethanol feeding in mice leads to intrahepatic fat (both
triglycerides and cholesterol) accumulation. In contrast, we see no histological
(Fig. 1; H&E and Oil Red O stains) or biochemical (hepatic triglycerides and
cholesterol) changes in P rats consuming ethanol ad libitum. The livers of both
groups (EtOH, n56; Control, n56) are virtually identical and show no
identifiable lipid globules, indicating that this level of alcohol usage did not result
in histological steatosis in the liver. Analysis of total hepatic triglycerides and
cholesterol in 6 EtOH livers and 5 controls further confirms this finding.
Triglyceride (Control group: 856¡92 mg triglycerides/mg protein, EtOH group:
863¡48 mg triglycerides/mg protein, p50.886) and cholesterol (Control group:
451¡27 mg cholesterol/mg protein, EtOH group: 469¡7.4 mg cholesterol/mg
protein, p50.219) levels were indistinguishable between the two groups.
Misregulation of genes important for cholesterol biosynthesis and
formation of the cytoskeleton
By design, this study emulates human alcohol consumption behaviors, creating an
ideal opportunity to catalog the global hepatic changes in gene expression that
occur in liver following chronic, moderate alcohol usage. Understanding these
alterations are paramount, as the liver metabolizes the majority of ingested alcohol
through a series of steps that oxidize ethanol into acetaldehyde and then into
acetate [19, 20]. To document the full complement of altered transcripts, we
compared the hepatic transcriptome of six animals that had free-choice access to
alcohol and six control individuals. All samples were pooled and paired-end
sequenced in a single lane, with individual samples identified by a unique barcode.
Fig. 1. Histological analysis of livers. Liver sections were stained using Oil Red O and Harris hematoxylin.
(A) and (B) Representative images of H2O animal livers. (C) and (D) Representative images of EtOH livers.
There is no evidence of hepatic steatosis in the livers of EtOH animals following 23 weeks of ethanol
exposure. The scale bar is 200 mm.
doi:10.1371/journal.pone.0110501.g001
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Samples averaged 13.1 million reads, and yielded an average of 1.2 Gb of sequence
per sample. Approximately 67% of reads mapped to our reference genome, 97%
of which mapped uniquely. Both groups shared 19,410 transcripts; an additional
1,456 transcripts were only detected in the water controls, while 1,546 transcripts
were unique to EtOH animals.
Alcohol-exposure led to altered expression of 259 transcripts from 258 genes,
with a false discovery rate (FDR) of 5% (S1 Table). The majority of these
transcripts (215) were down-regulated, while 44 were up-regulated in ethanol-
treated animals. We determined the potential functional consequences of these
altered transcription levels by gene ontology analysis using the MetaCore platform
from Thomson Reuters. To achieve greater biological significance, we restricted
our input to genes demonstrating a fold-change greater than ¡1.3. This reduced
the list to 94 transcripts (74 down-regulated and 20 up-regulated, Table 1) from
16 significantly altered pathways (Table 2). The cholesterol biosynthesis pathway
(Fig. 2) contained 12 misregulated genes (with a¡1.3 fold cut-off) and was the
most prominent pathway (p53.635e-14). Other pathways included: regulatory
aspects of cellular metabolism, with a bias for lipid and ketone metabolism; and
components of the cytoskeleton, particularly microfilaments and microtubules.
The level of ethanol consumption seen in our animals had an extensive effect on
the genes underlying the cholesterol biosynthesis pathway (Table 2; Fig. 2). In
Fig. 2: orange arrowheads represent enzymes encoded by their respective genes; all
enzymes in this pathway had a positive effect on their individual chemical
reactions (grey boxes), in other words catalyzing the reaction (represented by
green arrows labeled Z); chemical compounds are represented by purple
hexagons; blue boxes display other pathways linked via various metabolites. All
genes from the pathway elicited in our RNA-Seq study were down-regulated and
are circled; blue circles are genes with fold changes greater than 21.3 fold, and
green circles are those with a fold change less than 21.3.
The entirety of the cholesterol biosynthesis pathway occurs in the cytoplasm
and begins with acetyl-CoA (black circle at top center). First, the mitochondrial
enzyme acetyl-CoA acetyltransferase (Acat1, not altered in our study) catalyzes the
formation of acetoacetyl-CoA from two acetyl-CoA molecules. Next, hydro-
xymethylglutaryl-CoA (HMG-CoA) synthase 1 (Hmgcs1, 22.06 fold change)
catalyzes the conversion of acetoacetyl-CoA and acetyl-CoA to HMG-CoA. Then,
HMG-CoA reductase (Hmgcr, 21.63 fold change) catalyzes the formation of
NADP+ and mevalonic acid from HMG-CoA, NA(P)H and H+. Hmgcs1 and
Hmgcr are both considered rate-limiting steps in cholesterol synthesis [21].
Following this, mevalonate kinase (Mvk, not altered) activates an ATP-dependent
phosphorylation of mevalonic acid to mevalonate 5-phosphate, which is
phosphorylated by phosphomevalonate kinase (Pmvk, not altered) to form 5-
diphosphomevalonate. Hmgcr, Mvk, and Pmvk are all peroxisomal enzymes (pink
ovals). Diphosphomevalonate decarboxylase (Mvd, 22 fold change) decarbox-
ylates 5-diphosphomevalonate to isopentenyl pyrophosphate (IPP). At this point
the pathway splits into parallel options. In the first branch, IPP delta isomerase 1
(Idi1,22.05 fold change) and IPP delta isomerase 2 (Idi2, not altered) convert IPP
Moderate Alcohol Intake Represses the Hepatic Cholesterol Pathway
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Table 1. Genes with ¡1.3 or greater fold change after chronic ethanol treatment.
Symbol Gene Name Fold Change Corrected p-value
Aacs Acetoacetyl-CoA synthetase 22.4913 0.0090
Abcc4 ATP-binding cassette, subfamily C (CFTR/MRP), member 4 21.7972 0.0287
Acat3 Acetyl-Coenzyme A acetyltransferase 3 21.9462 0.0113
Acsm2 Acyl-CoA synthetase medium-chain family member 2A 21.7458 0.0311
Actg1 Actin, gamma 1 21.3990 0.0106
Aldh1a7 Aldehyde dehydrogenase family 1, subfamily A7 28.0352 0.0226
Ankrd44 Ankyrin repeat domain 44 1.4922 0.0442
Apex1 APEX nuclease (multifunctional DNA repair enzyme) 1 21.4432 0.0262
Arhgap29 Rho GTPase activating protein 29 1.3020 0.0415
Arl5b ADP-ribosylation factor-like 5B 1.3029 0.0324
Basp1 Brain abundant, membrane attached signal protein 1 21.6695 0.0131
Bckdk Branched chain ketoacid dehydrogenase kinase 21.3679 0.0056
Bcl3 B-cell CLL/lymphoma 3 21.4100 0.0393
Cbs Cystathionine beta synthase 21.3411 0.0415
Creb3l1 cAMP responsive element binding protein 3-like 1 21.3710 0.0324
Csad Cysteine sulfinic acid decarboxylase 22.3927 0.0463
Csmd1 CUB and Sushi multiple domains 1 22.3761 0.0157
Cyp51 Cytochrome P450, family 51 21.5255 0.0056
D3ZT51 21.4147 0.0415
Dguok Deoxyguanosine kinase * 0.0009
Dhcr24 24-dehydrocholesterol reductase 21.3771 0.0391
Dhcr7 7-dehydrocholesterol reductase 21.9364 0.0307
Dph1 DPH1 homolog (S. cerevisiae) 21.4021 0.0392
Efhc1 EF-hand domain (C-terminal) containing 1 # 0.0055
Ephb1 Eph receptor B1 # 0.0262
Fam73b Family with sequence similarity 73, member B 21.3103 0.0452
Fdft1 Farnesyl diphosphate farnesyl transferase 1 21.5468 0.0105
Fdps Farnesyl diphosphate synthase 21.4441 0.0095
Gck Glucokinase 22.1995 0.0080
Gclc Glutamate-cysteine ligase, catalytic subunit 21.3119 0.0182
Gm6484 Predicted gene 6484 21.8603 0.0195
Gpatch3 G patch domain containing 3 21.3652 0.0476
Gsta3 Glutathione S-transferase alpha 3 21.5341 0.0415
Hes6 Hairy and enhancer of split 6 (Drosophila) 21.5687 0.0416
Hip1r Huntingtin interacting protein 1 related 21.3085 0.0080
Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase 21.6268 0.0324
Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 22.0623 0.0064
Hsd17b7 Hydroxysteroid (17-beta) dehydrogenase 7 21.5221 0.0480
Idi1 Isopentenyl-diphosphate delta isomerase 1 22.0524 0.0056
Irs2 Insulin receptor substrate 2 1.6998 0.0415
Itgal Integrin, alpha L 1.3163 0.0339
Kif26b Kinesin family member 26B 23.0480 0.0350
Klf9 Kruppel-like factor 9 1.4918 0.0195
LOC100359951 21.3843 0.0415
Moderate Alcohol Intake Represses the Hepatic Cholesterol Pathway
PLOS ONE | DOI:10.1371/journal.pone.0110501 December 26, 2014 6 / 23
Table 1. Cont.
Symbol Gene Name Fold Change Corrected p-value
LOC100361376 21.4853 0.0389
LOC494499 21.5858 0.0441
LOC682888 21.4953 0.0172
Lss Lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) 21.5008 0.0022
Me1 Malic enzyme 1, NADP(+)-dependent, cytosolic 21.7325 0.0308
Mid1ip1 MID1 interacting protein 1 (gastrulation specific G12 homolog (zebrafish)) 21.5504 0.0262
Mrps18b Mitochondrial ribosomal protein S18B 21.3708 0.0262
Mrps2 Mitochondrial ribosomal protein S2 21.3651 0.0009
Mrps34 Mitochondrial ribosomal protein S34 21.3264 0.0365
Mvd Mevalonate (diphospho) decarboxylase 22.0150 0.0195
Nabp1 Oligonucleotide/oligosaccharide-binding fold containing 2A 21.3573 0.0255
Ndufaf4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 4 21.3623 0.0106
Oat Ornithine aminotransferase 1.3563 0.0324
Olr1587 Olfactory receptor 1587 7.9442 0.0415
Pam Peptidylglycine alpha-amidating monooxygenase 1.3639 0.0324
Pck1 Phosphoenolpyruvate carboxykinase 1 (soluble) 1.7312 0.0090
Pcsk9 Proprotein convertase subtilisin/kexin type 9 21.3723 0.0324
Pinx1 PIN2/TERF1 interacting, telomerase inhibitor 1 21.4089 0.0375
Pir Pirin (iron-binding nuclear protein) 21.9381 0.0370
Ppp1r3b Protein phosphatase 1, regulatory subunit 3B 21.3082 0.0195
Psat1 Phosphoserine aminotransferase 1 21.7933 0.0450
Psme3 Proteasome (prosome, macropain) activator subunit 3 1.6157 0.0171
Ptcd2 Pentatricopeptide repeat domain 2 21.3706 0.0056
Ptpre Protein tyrosine phosphatase, receptor type, E * 0.0056
Rrm2 Ribonucleotide reductase M2 2.4855 0.0434
Sc4mol Methylsterol monooxygenase 1 21.9263 0.0056
Scly Selenocysteine lyase 21.3971 0.0113
Scn1b Sodium channel, voltage-gated, type I, beta 21.4340 0.0056
Sds Serine dehydratase 2.4717 0.0441
Sds Serine dehydratase 4.7055 0.0114
Sema3d Sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3D
* 0.0044
Sert1 (AF077195) Sertoli cell protein 1 210.2588 0.0415
Sfrs2 Serine/arginine-rich splicing factor 2 21.3264 0.0169
Sfrs3 Serine/arginine-rich splicing factor 3 21.4130 0.0072
Sqle Squalene epoxidase 22.1774 0.0056
Srebf1 Sterol regulatory element binding transcription factor 1 21.5895 0.0420
Tcp11l2 T-complex 11 (mouse) like 2 1.3396 0.0499
Tlr13 Toll-like receptor 13 1.6008 0.0480
Tmem97 Transmembrane protein 97 21.4464 0.0142
Tsku Tsukushi 22.1529 0.0182
Tuba1c Tubulin, alpha 1C 21.3522 0.0476
Tuba4a Tubulin, alpha 4A 21.6102 0.0098
Tubb2a Tubulin, beta 2A class IIa 21.6534 0.0113
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to dimethylallyl diphosphate (DMAPP). Idi1 and Idi2 are both peroxisomal (blue-
pink ovals). DMAPP is condensed to geranyl diphosphate and to farnesyl
diphosphate. Both reactions are catalyzed by either farnesyl diphosphate synthase
(Fdps, 21.44 fold change) or geranylgeranyl diphosphate synthase 1 (Ggps1, not
altered). Alternatively, IPP can be converted to geranylgeranyl diphosphate by
Ggps1. A third option is the conversion of IPP to geranyl diphosphate and then to
farnesyl diphosphate by Fdps. Lastly, IPP can be converted directly to farnesyl
diphosphate by Ggps1.
All reactions culminate in the production of farnesyl disphosphate, which is
then converted to presqualene diphosphate followed by squalene; both reactions
are catalyzed by farnesyl diphosphate farnesyl transferase 1 (Fdft1, 21.55 fold
change). Fdft1 is located in the endoplasmic reticulum. From there squalene
epoxidase (Sqle, 22.18 fold change) and lanosterol synthase (Lss, 21.50 fold
change), both lysosomal enzymes, convert squalene to squalene-2-3-epoxide and
then to lanosterol. A series of three steps involving Cyp51 a cytochrome P450 gene
(21.53 fold change), transmembrane 7 superfamily member 2 (Tm7sf2, not
altered) and methylsterol monooxygenase 1 (Sc4mol, 21.93 fold change) leads to
the sequential conversion of lanosterol to 4,4-di(oxomethyl)cholesta-8,24-dienol.
Following that, NAD(P) dependent steroid dehydrogenase-like (Nsdhl, 21.18 fold
change), emopamil binding protein (sterol isomerase) (Ebp, 21.23 fold change)
and sterol-C5-desaturase (Sc5dl, 21.25 fold change) produce 7-dehydrodesmos-
terol from 4,4-di(oxomethyl)cholesta-8,24-dienol. Then, 7-dehydrocholesterol
reductase (Dhcr7, 21.94 fold change) and 24-dehydrocholesterol reductase
(Dhcr24, 21.38 fold change) remove the C(7–8) double bond and delta-24 double
bond, respectively, to produce cholesterol (black circle, bottom center). Dhcr24
may reduce the double bond in many of the cholesterol intermediates beginning
with lanosterol, creating a variety of alternative steps. However, these alternatives
are catalyzed by the same enzymes in the same order (lower half of Fig. 2).
Our RNA-seq studies demonstrated that ethanol exposure down-regulated 15
of the 21 genes in the cholesterol biosynthesis pathway, including Hmgcr and
Hmgcs1. Three of these genes, Nsdhl, Ebp, and Sc5dl, were identified in our RNA-
Seq data but were excluded from MetaCore analysis because they failed to make
Table 1. Cont.
Symbol Gene Name Fold Change Corrected p-value
Tubb4b Tubulin, beta 4B class IVb 21.3448 0.0216
Upp2 Uridine phosphorylase 2 15.3404 0.0202
Wdr18 WD repeat domain 18 21.3181 0.0182
Yars Tyrosyl-tRNA synthetase 21.4044 0.0098
Zbtb43 Zinc finger and BTB domain containing 43 1.3794 0.0337
Zfand2a Zinc finger, AN1-type domain 2A 21.3342 0.0407
Zmynd19 Zinc finger, MYND-type containing 19 21.3301 0.0339
* - Gene was solely expressed in water control. # - Gene was solely expressed in ethanol treatment.
doi:10.1371/journal.pone.0110501.t001
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the cutoff of 21.3 X alteration in expression, leaving a total of 12 genes in the
cholesterol biosynthesis pathway for further study. We re-analyzed these 12 genes
quantitatively using TaqMan chemistry to confirm ethanol-induced changes in
expression. We chose 18S rRNA for our endogenous control, as it displays the
least amount of variance in all stages of alcoholic liver disease in humans
(compared to GAPDH, ACTB, and SFRS4 [22]). For each gene, we performed
qRT-PCR on 5 or 6 biological replicates. One technical replicate was included for
each biological sample to control for pipetting errors. We selected genes based on
gene ontology analysis, i.e. cholesterol metabolism and cellular infrastructure
(Table 2).
These studies confirmed that nine members of the cholesterol biosynthesis
pathway were down-regulated in qRT-PCR studies (Fig. 3A). The three
exceptions were Fdps, which catalyzes the production of geranyl pyrophosphate
and farnesyl pyrophosphate from isopentenyl pyrophosphate and dimethylallyl
pyrophosphate, Hmgcs1, which synthesizes acetyl-CoA, acetoacetyl-CoA, and
H2O, and Lss, which forms lanosterol. None of these were significantly altered by
qRT-PCR. We then examined two transcription factors that aid in the regulation
of cholesterol homeostasis (Fig. 3B): Srebf1, which activates many cholesterol
biosynthesis genes [21]; and Ppara, which activates genes orchestrating lipid
Table 2. GeneGO pathway map analysis.
# Pathway Genes p-value
1 Cholesterol Biosynthesis Cyp51, Dhcr24, Dhcr7, Fdft1, Fdps, Hmgcr, Hmgcs1, Idi1, Lss, Mvd,
Sc4mol, Sqle
3.99E-14
2 Cytoskeleton remodeling_Neurofilaments Actg1, Tuba1c, Tuba4a, Tubb2a, Tubb4b 1.08E-05
3 Cell adhesion_Gap Junctions Actg1, Tuba1c, Tuba4a, Tubb2a, Tubb4b 2.28E-05
4 Cytoskeleton remodeling_Keratin filaments Actg1, Tuba1c, Tuba4a, Tubb2a, Tubb4b 4.78E-05
5 Regulation of metabolism_Bile acids regulation of
glucose and lipid metabolism via FXR
Me1, Pck1, Srebf1 5.34E-05
6 wtCFTR and D508 traffic/Clathrin coated vesicles
formation (norm and CF)
Actg1, Hip1r 1.58E-04
7 Development_Role of IL-8 in angiogenesis Actg1, Hmgcr, Srebf1 3.14E-04
8 Butanoate metabolism Aacs, Hmgcs1, Acat3 4.31E-04
9 Mitochondrial ketone bodies biosynthesis and metabo-
lism
Aacs, Hmgcs1, Acat3 4.61E-04
10 Development_Slit-Robo signaling Actg1, Tuba1c, Tuba4a, Tubb2a, Tubb4b 6.33E-04
11 Cytoskeleton remodeling_Reverse signaling by ephrin
B
Actg1, Tuba1c, Tuba4a, Tubb2a, Tubb4b 6.98E-04
12 Cell cycle_Role of Nek in cell cycle regulation Tuba1c, Tuba4a, Tubb2a, Tubb4b 7.67E-04
13 Regulation of lipid metabolism_Regulation of lipid
metabolism via LXR, NF-Y and SREBP
Cyp51, Srebf1 1.27E-03
14 Regulation of lipid metabolism_Insulin regulation of fatty
acid metabolism
Gck, Irs2, Srebf1 1.59E-03
15 Transport_Macropinocytosis Actg1, Tuba1c, Tuba4a, Tubb2a, Tubb4b 2.02E-03
16 Regulation of lipid metabolism_Regulation of fatty acid
synthase activity in hepatocytes
Srebf1 5.11E-03
doi:10.1371/journal.pone.0110501.t002
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oxidation [23]. We confirmed that Srebf1 was significantly decreased (p50.0009).
Although Ppara was not identified in our RNA-Seq data, it was significantly up-
regulated by qRT-PCR (p50.0024).
We also confirmed altered expression of five actin and tubulin genes (Actg1,
Tuba1c, Tuba4a, Tubb2a, Tubb4b), which are key components of seven additional
pathways (Table 2# 2–4, 10–12, 15). Actg1 is a cytoplasmic actin and a subunit of
microfilaments involved in internal motility. Alpha and beta tubulins (Tuba1c,
Tuba4a, Tubb2a, Tubb4b) are the major constituents of microtubules, which
provide the scaffold for organelle organization and protein trafficking. Four of
these (Actg1, Tuba1c, Tuba4a, Tubb2a), showed altered expression by both RNA-
Seq and qRT-PCR (Fig. 3C).
It is well documented that the gene product of Cytochrome P450 2E1 (Cyp2e1) is
responsive to high levels of ethanol consumption, resulting in increased
generation of reactive oxygen species (ROS) [24, 25]. High levels of ROS increase
oxidative stress in the cell, which likely promotes the various hepatic injuries seen
following high levels of alcohol consumption [26, 27]. Although we did not
examine ROS, we found a significant (1.22 fold; p50.0044, Fig. 3D) increase in
expression of Cyp2e1 by qRT-PCR.
To ensure there was not a technical bias in the data, as most genes were down-
regulated in the alcohol group, we confirmed two up-regulated genes, Irs2 and
Pck1. These genes are involved in regulating glucose and lipid metabolism
(Table 3) and were up-regulated in both analyses (Fig. 4A). Lastly, we used qRT-
PCR to confirm the genes with the greatest fold change in both directions;
Olr1587, Sds, and Upp2 were increased, while Aldh1a7, Kif26b, and Sert1 were
decreased (Fig. 4B, C) by both measurements.
Discussion
To the best of our knowledge, this is the first study to use RNA-Seq to analyze the
hepatic transcriptome following chronic alcohol exposure. RNA-Seq overcomes
many of the limitations of hybridization-based methods. NGS data has lower
noise, provides accuracy over a wide range of expression levels [28], and removes
the dependence on species with well annotated genomes [29]. We validated the
use of RNA-Seq via qRT-PCR confirmation of 28 genes in multiple genetic and
biochemical pathways.
Fig. 2. The cholesterol biosynthesis pathway. Moderate alcohol consumption decreased expression of 15 genes throughout the cholesterol biosynthesis
pathway. Blue circles denote genes with a fold change greater than 21.3, while green denote those less than 21.3. All enzymes (orange arrowheads)
produced from these genes catalyzed (green arrows labeled Z) their respective chemical reactions (grey boxes) on their target compounds (purple
hexagons). The first compound, Acetyl-CoA, and the last compound, Cholesterol, are denoted by black circles (top and bottom of figure, respectively). The
figure also displays the cellular localization of the enzymes: the entire figure is found in the cytoplasm, pink ovals represent peroxisomes (e.g. IDI1), blue
ovals are lysosomes (e.g. LSS), and pink stacks represent endoplasmic reticulum (e.g. FDFT1). Srebf1 and Srebf2, transcription factors that activate many
of these genes, were both down-regulated (not displayed). Nine of these results were confirmed by qRT-PCR (Fig. 3A). Image modified from Thomson
Reuter’s MetaCore.
doi:10.1371/journal.pone.0110501.g002
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Free-choice alcohol consumption closely reflects alcohol use behavior in
humans [12, 30]. A caveat of voluntary consumption is that most outbred rodents
consume only low, and therefore pharmacologically irrelevant levels of alcohol.
We avoided this issue by using inbred iP10a rats as test subjects and providing
animals free access to multiple concentrations of ethanol solution [31], as
Fig. 3. Confirmation of altered expression by qRT-PCR in functional pathway genes. Taqman-based qRT-PCR was used to confirm the changes in
gene expression. These graphs display the fold change (¡SEM) of the candidate genes by qRT-PCR (red bars) and RNA-Seq (black bars) analysis for
comparison. Numbers are relative to the water treated control rats (set at 1.0). (A) Nine of twelve genes in the cholesterol biosynthesis pathway were
confirmed. (B) Ppara, a transcription factor that activates genes for cholesterol oxidation was not significantly altered by RNA-Seq analysis, but was
significantly up-regulated by qRT-PCR. Srebf1, a transcriptioin factor that activates many genes in the synthesis pathway, was significantly decreased in
both analyses. (C) Four cytoskeleton subunit genes were suppressed by RNA-Seq and qRT-PCR. (D) Cyp2e1, a gene induced by chronic high levels of
alcohol intake that mediates various alcohol-induced injuries was not induced when measured by RNA-Seq analysis, but was significantly up-regulated by
qRT-PCR. * - p-value ,0.05, ** - p-value ,0.005, *** - p-value ,0.0001.
doi:10.1371/journal.pone.0110501.g003
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providing multiple alcohol concentrations to P rats increases their ethanol intake
[32]. We also monitored consumption, measured absolutely by grams of ethanol/
kg/day, to ensure that all animals consumed relevant quantities. Animals
voluntarily consumed an average of 7.4 g ethanol/kg/d during the first 12 weeks.
This level of intake produced BACs ranging from 50–90 mg/dL. Consumption
during the subsequent 11 weeks was estimated based on prior data. We did not
use a pair-feeding strategy to equalize the caloric intake for the EtOH or H2O
groups, as P rats self-regulate their calorie intake by reducing chow intake to
compensate for the calories from the ethanol solution (L. Lumeng, unpublished
data). We collected body weights measurements throughout the first 12 weeks of
the study (data not shown), and found no differences between the controls and
alcohol-treated animals at any timepoint. Although this does not preclude
differences in intake, it suggests that the animals receiving free-choice alcohol
were not consuming extra calories. As such, it is unlikely that differences in caloric
intake are responsible for these results.
Our data indicate that 23 weeks of free-choice alcohol consumption
significantly represses expression of genes involved in cholesterol biosynthesis and
cytoskeleton remodeling. Although altered expression does not necessarily reflect
a change in protein level, Deaciuc and colleagues [16] found that changes in
protein levels reflected altered expression for 4 out of 5 genes following four weeks
of forced ethanol exposure.
Hepatic Cholesterol and Triglycerides
High levels of alcohol intake (BACs$300 mg/dL) can cause severe fatty liver
(steatosis) following acute and chronic alcohol exposure in mice [18, 33].
Microarray studies conducted on animals following forced ethanol exposure (to
achieve high BACs and an inordinate degree of steatosis) reported altered
expression patterns that likely promote increased cholesterol synthesis in the liver
[16–18]. However, the present study, which was designed to assess the hepatic
transcriptome of animals undergoing a nonhazardous drinking paradigm,
detected no steatosis, normal hepatic cholesterol and triglyceride levels and a
suppression of steady-state mRNA levels of nine genes in the cholesterol synthesis
pathway (Tables 2.3 and 2.4), including HMG-CoA reductase (Hmgcr) and sterol
regulatory element binding transcription factor 1 (Srebf1). Hmgcr is the rate-
limiting enzyme for cholesterol synthesis activity in the liver and Srebf1 is the
activating transcription factor for many cholesterol synthesis genes [21].
These findings agree with Lakshmanan and Veech [34], who determined that
feeding ethanol in drinking water for 21 days caused a 29% decrease in Hmgcr,
presumably due to BACs that are much lower than those observed with forced
ethanol feeding. Long-term studies of the consequences of free-choice drinking in
P and iP rats indicates that there are minimal phenotypic liver insults at six
months [35], further supporting our findings.
It is beyond the scope of this paper to address exactly how down-regulation of
hepatic cholesterol synthesis genes can have a salutary effect on cardiovascular
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risks. However, it is well established that down-regulation of hepatic cholesterol
synthesis genes, as can be achieved by the use of statins, can consistently suppress
plasma LDL and raise circulating HDL. High circulating HDL levels are anti-
atherogenic because of ‘‘reverse cholesterol transport’’ [36]. Additionally,
moderate ethanol intake is associated with increases in paraoxonase 1 (PON1)
activity (plasma and liver) and expression (liver) [37]. PON1 is an HDL-
associated anti-atherogenic enzyme that inhibits the oxidation of LDL, mediates
the conversion of oxidized LDL to inactive products, and inhibits cholesterol
uptake by macrophages in the intima of atheromas [38]. Our results led us to
propose that moderate and nonhazardous alcohol drinking could provide the
same benefits as a statin, and thereby administer a significant cardioprotective
Table 3. TaqMan assays used for qRT-PCR confirmation.
Gene Name Sequence ID
Actg1 Actin, gamma 1 NM_001127449.1
Aldh1a7 Aldehyde dehydrogenase family 1, subfamily A7 NM_017272.15
Cyp2e1 Cytochrome P450, family 2, subfamily e, polypeptide 1 NM_031543.1
Cyp51 Cytochrome P450, family 51 NM_037073.1
Dhcr24 24-dehydrocholesterol reductase NM_001080148.1
Dhcr7 7-dehydrocholesterol reductase NM_022389.2
Fdft1 Farnesyl diphosphate farnesyl transferase 1 NM_019238.2
Fdps Farnesyl diphosphate synthase NM_031840.1
Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase NM_013134.2
Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase (soluble) NM_017268.1
Idi1 Isopentenyl-diphosphate delta isomerase 1 NM_053539.1
Irs2 Insulin receptor substrate 2 NM_001168633.1
Kif26b Kinesin family member 26B NM_001109079.2
Lss Lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) NM_031049.1
Mvd Mevalonate (diphospho) decarboxylase NM_031062.1
Olr1587 Olfactory receptor 1587 NM_001000913.1
Pck1 Phosphoenolpyruvate carboxykinase 1 (soluble) NM_198780.3
Ppara Peroxisome proliferator-activated receptor alpha NM_013196.1
Sc4mol Methylsterol monooxygenase 1 NM_080886.1
Sds Serine dehydratase NM_053962.3
Sert1 (AF077195) Sertoli cell protein 1 AF077195.1
Sqle Squalene epoxidase NM_017136.2
Srebf1 Sterol regulatory element binding transcription factor 1 XM_213329.5
Tuba1c Tubulin, alpha 1C NM_001011995.1
Tuba4a Tubulin, alpha 4A NM_001007004.1
Tubb2a Tubulin, beta 2A class IIa NM_001109119.1
Tubb4b Tubulin, beta 4B class IVb NM_199094.1
Upp2 Uridine phosphorylase 2 NM_001106481.1
18S 18S ribosomal RNA X03205.1
doi:10.1371/journal.pone.0110501.t003
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benefit. In addition to down-regulation of Hmgcr, moderate alcohol drinking in
the iP10a rats also led to decreased expression of eight other genes that are
important in hepatic cholesterol synthesis. Together, these data led to the
supposition that the protective effects (as visualized by the J- or U-shaped curves)
of long-term intake of nonhazardous amounts of alcohol could be due to
decreased hepatic biosynthesis of cholesterol, thereby suppressing circulating LDL
levels and raising plasma HDLs.
Alcohol Metabolism
One puzzling finding is that only one of the potential alcohol metabolism genes
(Aldh1a7) was upregulated in this study. Most alcohol is metabolized sequentially
from ethanol to acetaldehyde to acetate by two classes of enzymes: alcohol
dehydrogenases (ADH enzymes) and aldehyde dehydrogenases (ALDH enzymes)
[19]. ADH enzymes function in the cytosol, converting ethanol to acetaldehyde
through a NAD+ dependent mechanism. Approximately 85 to 90% of alcohol is
metabolized by ADH enzymes to acetaldehyde in the cytosol [19]. Secondary
hepatic alcohol metabolizing enzymes include catalase, which processes ,2% of
hepatic alcohol into acetaldehyde in the peroxisome fraction and a handful of
cytochrome P450 enzymes (CYP2E1, CYP1A2 and CYP3A4) that oxidize ,10%
of total ingested alcohol to acetaldehyde within the endoplasmic reticulum.
We saw no changes in expression of any of the Adh genes, but did see increased
expression of Cyp2e1 by qRT-PCR, indicating that chronic alcohol consumption
could be causing a shift from cytosolic metabolism to oxidation within the
endoplasmic reticulum. Usually, Cyp2e1 is induced by heavy ethanol consumption
Fig. 4. Altered expression by qRT-PCR. (A) Irs2 and Pck1, involved in the regulation of lipid metabolism, were up-regulated by RNA-Seq analysis and
confirmed by qRT-PCR. (B) and (C) confirm the genes with the greatest up-regulation and down-regulation, respectively. The direction of the change was
confirmed for all 6 genes, though not necessarily to the same degree. ** - p-value ,0.005, *** - p-value ,0.0001.
doi:10.1371/journal.pone.0110501.g004
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[39–41]; in our study, the animals followed a moderate, chronic alcohol intake.
How chronic ethanol administration leads to induction of Cyp2e1 remains
controversial. Elevated levels of Cyp2e1 mRNA have been reported in some studies
[42], while others have reported little or no induction of Cyp2e1 mRNA [43, 44]
following a chronic alcohol paradigm. In P animals, CYP2E1 studies show
elevated protein and enzyme activity levels following six months of free-choice
drinking, with consumption levels at 8 to 9 g/kg/d [35]. These conditions closely
mimic our study, and suggest that alcohol can be metabolized by CYP2E1 in P
rats.
One byproduct of CYP2E1 metabolism is the production of reactive oxygen
species [19, 24, 25, 45]), which promote various cellular and DNA injuries [26, 27].
qRT-PCR studies indicated that chronic free-choice drinking increased mRNA
levels of Cyp2e1 by 22%. Future studies aimed at determining if increased
oxidative stress accompanied the upregulation of Cyp2e1 will be important to
better understand the pathophysiology associated with chronic, but moderate
alcohol consumption.
Acetaldehyde, the first oxidized product of alcohol metabolism, damages
multiple components of the cell, including DNA, where it induces intrastrand
cross-linkages [46]. Acetaldehyde is oxidized to acetate primarily by ALDH2
protein isoforms, called the Class II ALDH enzymes [47]. We saw no upregulation
of any of the ALDH genes, including the Class II ALDH2 isoforms. This, along
with the modest increase (22%) in Cyp2e1 expression, indicates that alcohol
metabolism overall had not changed, but the method of oxidation of ethanol to
acetaldehyde may have shifted slightly due to chronic ingestion.
Although we saw no evidence for a marked change in ethanol breakdown, we
detected a marked decrease in the steady-state levels of Aldh1b7 (an ,8 fold
reduction in alcohol-treated animals), a member of the Class I acetaldehyde
dehydrogenase family. The primary target of most of the Class I enzymes,
including Aldh1b7, is retinol, not acetyaldehyde [48]. Therefore, decreased levels
of Aldh1b7 mRNA may indicate that other oxidation reactions, but not alcohol
metabolism, are disrupted.
Cellular Cytoskeleton
Five structural genes involved in formation and function of the cytoskeleton
(Actg1, Tuba1c, Tuba4a, Tubb2a, Tubb4b) were downregulated in alcohol-treated
animals. The cytoskeleton, which is composed of microfilaments, intermediate
filaments and microtubules, provides a scaffold for cytoplasmic organization,
cellular trafficking and protein migration/motility. We found that chronic ethanol
consumption significantly down-regulated Actin, gamma 1 (Actg1) and several
alpha and beta tubulins (Tuba1c, Tuba4a, Tubb2a, Tubb4b). ACTG1 is a subunit
of microfilaments, while the tubulins are microtubule subunits. These findings
add to current discrepancies in the field; altered expression levels of several
tubulin genes have been reported in studies examining the effects of high doses of
alcohol. For example, various cytoskeleton and extracellular matrix genes,
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including Tubb2b, were down-regulated in Park’s study [49], in which a Lieber-
DeCarli diet was administered for 7 weeks. This is in agreement with our findings.
However, Deaciuc and colleagues [16] determined that Tuba1 and Tubb5 were
up-regulated after 4 weeks of intragastric ethanol infusion, while Yoon et al [50]
found no changes in the levels of a-tubulin following 8–17 weeks of a Lieber-
DeCarli diet. These differences imply that the specific quantity and duration of
alcohol exposure, not simply the presence of alcohol, are important determinants
for affecting expression of cytoskeleton genes. Our data suggest that expression of
several microfilament and microtubule subunit genes in hepatocytes are
exquisitely sensitive (even with BACs in the range of 50 to 90 mg/dL) to the effects
of ethanol.
Alterations in mRNA Steady State levels
Since only 17 of the 94 transcripts in this study showed large changes in gene
expression (.2 fold differences), we sought to gain a deeper understanding of the
genes outside of the major pathways that were most affected by chronic alcohol
consumption. We focused on Upp2 (15.3 fold induction), Orl1587 (7.9 fold
induction, Sds (4.7 fold induction), Sert1 (10.3 fold reduction) and Kif26b (3.0
fold reduction). We confirmed alterations in gene expression in all of these
transcripts. We then looked for phenotypes that could be important for our study
using The Phenotype-Genotype Integrator (PheGenI) [51] and PhenoGen
Informatics [52]. PheGenI merges NHGRI genome-wide association study
(GWAS) catalog data with databases housed at the National Center for
Biotechnology Information (NCBI), including Gene, dbGaP, OMIM, GTEx and
dbSNP. PheGenI can be accessed from: http://www.ncbi.nlm.nih.gov/gap/
phegeni. PhenoGen Informatics, a separate website for quantitative analysis of
transcriptome data, is housed at the University of Colorado Denver; PhenoGen
Website [Internet]. Aurora (CO): University of Colorado and Denver Health
Sciences Center. PhenoGen Informatics, 2005 - [cited (7–2014)]. PhenoGen
Informatics is available from http://phenogen.ucdenver.edu.
Using PheGenI, we found an eQTL overlapping Upp2 (uridine phosphorylase
2) that is associated with several phenotypes, including cardiovascular disease,
atherosclerosis, stroke and obesity. This case-cohort study entitled, ‘‘Building on
GWAS for NHLBI-diseases: the U.S. CHARGE consortium (CHARGE-S): FHS’’ is a
sub-study from the Framingham cohort and is deposited into dbGAP (Accession
# phs000651.v3.p8; Database of Genotypes and Phenotypes. Bethesda, (MD):
National Center for Biotechnology Information, National Library of Medicine)
[53]. dbGAP can be accessed at: http://www.ncbi.nlm.nih.gov/sites/
entrez?db5gap.
PheGenI analysis of Kif26b (Kinesin family member 26b) revealed that 50
different studies had identified eQTLs associated with this genomic region. Eleven
of these studies found associations with cholesterol and/or lipoproteins, while
twenty showed strong associations with coronary disease and/or atherosclerosis.
Other common associations include cardiovascular disease, obesity, gout and
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stroke. Although Olr1587 is an olfactory receptor that is usually detected in the
olfactory bulb, several eQTLs (identified by PhenoGen Informatics analysis)
overlap the region, including a 2 Mb eQTL associated with increased serum
triglycerides and a 45 Mb eQTL associated with alcohol response. No associations
were found with Sds (serine dehydratase) or Sert1 (sertoli cell transcript 1, a
putative rat transcript that has not been identified in mouse or human).
Conclusions
Free-choice alcohol drinking in alcohol-preferring P rats simulates moderate,
nonhazardous alcohol drinking in humans. We identified 94 genes with
alterations in gene expression at a false discovery rate of 5%. The majority of these
alterations showed less than a 2-fold change in expression, including most of the
genes within the cholesterol biosynthesis pathway. This information was taken
into consideration during MetaCore analysis. One explanation is that subtle
changes in gene expression along a large pathway could produce amplified effects
on cholesterol production. In support of this possibility, we saw no evidence of
steatosis in the alcohol-treated animals. This is in stark contrast to other studies
using much larger quantities of alcohol [18, 33] that reported high levels of
steatosis and gene expression patterns consistent with increased hepatic
cholesterol synthesis [16–18]. Since these animals were under selection for 30
generations prior to brother-sister matings to produce inbred lines [54], one
could predict that reducing cholesterol production beyond a certain threshold
could have deleterious effects during the selection process.
Three of the five genes outside of the cholesterol, lipid or cytoskeleton pathways
showing large increases or decreases in expression are associated with eQTLs for
cardiovascular disease, coronary disease atherosclerosis and stroke, phenotypes
that are highly relevant for this study. It is possible that misregulation of these
strong candidates, along with a downregulation of the cholesterol pathway,
explains, at least in part, the well-documented J- or U-shaped relationship
between alcohol exposure and cardiovascular risks seen in humans. Although
these initial studies were conducted in the liver, further experimentation of the
epigenetic and genetic consequences of free-choice drinking in other tissues (e.g.
the brain) is important to understand the molecular underpinnings of the
behavioral consequences of long-term, voluntary alcohol drinking.
Materials and Methods
Ethics Statement
All procedures and treatments on live animals were conducted in facilities
approved by the American Association for the Accreditation of Laboratory
Animals with approval from the Indiana University School of Medicine Animal
Care and Use Committee, protocol #, and complied with the IUSM IACUC
guidelines, protocol # 0000003015.
Moderate Alcohol Intake Represses the Hepatic Cholesterol Pathway
PLOS ONE | DOI:10.1371/journal.pone.0110501 December 26, 2014 18 / 23
Rat Strains, Animal Husbandry and Alcohol Treatment
Twelve adult females from the 65th generation of the inbred, alcohol-preferring,
iP10a rats were divided evenly between ethanol treatment (EtOH) and water
control (H2O) groups. This inbred alcohol-preferring (iP) strain was raised by
repeated brother X sister matings when the P line reached the S30 generation of
selective breeding. Chronic alcohol exposure for the EtOH group was achieved by
23 weeks of continuous access to 0, 10, 20 and 30% ethanol (v/v) in their home
cage. Ethanol consumption at each concentration was monitored three times per
week, and body weight was measured weekly for the first 12 weeks. EtOH animals
consumed a daily average of 7.43 g ethanol/kg in the first 12 weeks. BACs ranged
from 50–90 mg/dL. Animals were housed in hanging wire mesh cages with access
to food (Teklad Irradiated F-6 Rodent Diet), tap water, and alcohol solutions ad
libitum. The rat room followed a 12:12 light:dark cycle.
Tissue Procurement
To prevent a spike in stress response during sacrifice, animals were habituated to daily
handling and the guillotine for two weeks prior to euthanasia. Immediately after
sacrifice, livers were snap frozen in a bath of isopentane and dry ice. Tissue was stored
at 280 C˚ until RNA isolation. BACs were undetectable at the time of sacrifice.
Hepatic Triglyceride and Cholesterol Analysis
We inspected Oil Red O and hematoxylin stained slides using Aperio’s
ImageScope (Vista, CA) to identify lipids. We used approximately 20 mg of liver
tissue powder, prepared under liquid nitrogen, for quantifying triglyceride and
cholesterol levels. Lipids were extracted using isopropanol. Hepatic triglycerides
and cholesterol were measured using Wako L-type TG M and Cholesterol E (Cat
#439–17501) assay kits, respectively (Wako Diagnostics, Richmond, VA).
RNA Isolation
Total RNA was isolated from frozen liver samples using RNA Stat-60 (Amsbio
LLC, Lake Forest, CA) following the manufacturer’s directions and stored at
280 C˚. Integrity was checked using the Agilent 2100 Bioanalyzer (Agilent
Technology, Santa Clara, CA). All samples showed an RNA integrity number
above 8.5.
RNA-Sequencing
The Illumina TruSeq RNA kit was used for cDNA library preparation, largely
following the manufacturer’s directions with modifications detailed below.
Poly(A) RNA was isolated by annealing biotinylated oligo-dT to total RNA
followed by two purification cycles using streptavidin-conjugated magnetic beads.
RNA was fragmented for 4 minutes at 94 C˚ to increase the population of desired
sized RNA fragments in the 200–600 nt range. cDNA synthesis was performed
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using random hexamers. Fragment ends were repaired and 39 ends were
adenylated prior to adaptor ligation. Each adaptor was uniquely bar-coded to
assign each read to its respective sample during data analysis. Adaptor ligated
fragments were enriched following 10 cycles of PCR. Resulting amplicons were
pooled and size selected using a PippinPrep (Sage Science, Beverly, MA) set to
collect 320–600 bp molecules. The final cDNA library was titrated by qRT-PCR
and sequenced in 101 nucleotide paired-end reads on an Illumina HiScanSQ
system. RNA-seq data has been deposited into the Gene Expression Omnibus
(GEO) Database at NCBI (Accession # GSE46669).
RNA-Seq Data Analysis
Sequences were analyzed and mapped using CLCbio Genomics Workbench 4.9
software (Cambridge, MA). Reads were normalized by reads per kilobase per
million mapped reads (RPKM) to standardize for gene length, as described in
Mortazavi [28]. Values were transformed by square root to stabilize variances and
renormalized a second time by quantile normalization to adjust for among sample
variation. A standard t-test with pooled error term was applied to determine p
values, which were then corrected for a false discovery rate (FDR) of 5%.
Quantitative RT-PCR
We used the samples from the RNA-Seq experiment to confirm gene expression
differences by qRT-PCR. Total RNA was treated with DNaseI using the Ambion
Turbo DNA-free kit (Cat #AM1907) following the manufacturer’s protocol (ABI,
Foster City, CA). cDNA was synthesized using the SuperScript VILO cDNA
Synthesis kit (Cat #11754050) following manufacturer’s instructions (Invitrogen,
Carlsbad, CA). Finally, qRT-PCR was performed using TaqMan gene expression
assays (Table 1) from ABI (Foster City, CA) on an ABI Prism 7000 Sequence
Detection System. Samples were normalized to the endogenous 18S rRNA control,
and expression was determined by relative quantification (fold change 522DDCt).
Data Analysis for qRT-PCR
The experimental design was a completely randomized design with a one-way
arrangement of treatments (water vs. ethanol consumption), which were applied
to a total of 5 or 6 animals. Data were analyzed through the Generalized Linear
Model (GLM) procedure on SAS and comparisons between treatments were done
through the Fisher’s Least Square Differences method.
Supporting Information
S1 Table. Genes statistically altered by chronic ethanol treatment. This table
includes all genes with a corrected FDR of 5%.
doi:10.1371/journal.pone.0110501.s001 (DOCX)
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